Surfix
Colin Bartel is the Chief Financial Officer at Surfix Diagnostics, a company that has developed an ultrasensitive photonic biosensor. Apart from their current role, Colin also serves as a Supervisory Board member at Fokker Technologies Group B.V. and is the owner and co-investor at W6 Finance. Colin has extensive experience in various financial roles, including positions at IamFluidics BV, Micronit Microtechnologies, and OPRA Technologies. Prior to these roles, Colin worked at AkzoNobel, The Growth Factory, Accenture, and Parcom Capital, where Colin gained valuable experience and expertise. Educated at Rotterdam School of Management, Erasmus University, and Queen's University, Colin holds an MBA, a Master’s Degree in Business Informatics, and a Bachelor of Science in Life Sciences.
This person is not in any offices
Surfix
1 followers
Surfix’s mission is to advance global health by delivering accurate, accessible, and affordable diagnostic solutions for disease detection and management, specifically in underserved Point-of-Care (POC) testing segments. To achieve this goal, Surfix has developed a photonic diagnostics platform that delivers exceptional sensitivity, accuracy, and a broad dynamic range. This cutting-edge technology enables diagnostics with precision surpassing traditional laboratory standards – a POCT with beyond lab-level precision.